Mesenchymal stromal cell therapy for COVID-19 acute respiratory distress syndrome: a double-blind randomised controlled trial – Bone Marrow Transplantation

  • Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323:2052–9.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Petrilli CM, Jones SA, Yang J, Rajagopalan H, O’Donnell L, Chernyak Y, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020;369:m1966.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Spagnolo P, Balestro E, Aliberti S, Cocconcelli E, Biondini D, Della CG. et al. Pulmonary fibrosis secondary to COVID-19: a call to arms? Lancet Respir Med. 2020;8:750–2.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. N Engl J Med. 2020;383:2451–60.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384:693–704.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Mathew D, Giles JR, Baxter AE, Oldridge DA, Greenplate AR, Wu JE, et al. Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science (80-). 2020;369:eabc8511.

    Article 
    CAS 

    Google Scholar
     

  • Del Valle DM, Kim-Schulze S, Huang H-H, Beckmann ND, Nirenberg S, Wang B, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. 2020;26:1636–43.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Jiang W, Xu J. Immune modulation by mesenchymal stem cells. Cell Prolif. 2020;53:1–16.

    Article 

    Google Scholar
     

  • Squillaro T, Peluso G, Galderisi U. Clinical trials with mesenchymal stem cells: an update. Cell Transpl. 2016;25:829–48.

    Article 

    Google Scholar
     

  • Leibacher J, Henschler R. Biodistribution, migration and homing of systemically applied mesenchymal stem/stromal cells Mesenchymal Stem/Stromal Cells – An update. Stem Cell Res Ther. 2016;7:1–12.

    Article 

    Google Scholar
     

  • Matthay MA, Calfee CS, Zhuo H, Thompson BT, Wilson JG, Levitt JE, et al. Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial. Lancet Respir Med. 2019;7:154–62.

    Article 
    PubMed 

    Google Scholar
     

  • Chen J, Hu C, Chen LL, Tang L, Zhu Y, Xu X, et al. Clinical study of mesenchymal stem cell treatment for acute respiratory distress syndrome induced by epidemic influenza A (H7N9) infection: a hint for COVID-19 treatment. Engineering. 2020;6:1153–61.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Kirkham AM, Bailey AJM, Monaghan M, Shorr R, Lalu MM, Fergusson DA, et al. Updated living systematic review and meta-analysis of controlled trials of mesenchymal stromal cells to treat COVID-19: a framework for accelerated synthesis of trial evidence for rapid approval-FASTER approval. Stem Cells Transl Med. 2022;11:675–87.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Payares-Herrera C, Martínez-Muñoz ME, Vallhonrat IL, de Molina RM, Torres MP, Trisan A, et al. Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): a structured summary of a study protocol for a randomised controlled trial. Trials. 2021;22:20–2.

    Article 

    Google Scholar
     

  • Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, et al. Acute respiratory distress syndrome: The Berlin definition. J Am Med Assoc. 2012;307:2526–33.


    Google Scholar
     

  • Gonzalo-Daganzo R, Regidor C, Martín-Donaire T, Rico MA, Bautista G, Krsnik I, et al. Results of a pilot study on the use of third-party donor mesenchymal stromal cells in cord blood transplantation in adults. Cytotherapy. 2009;11:278–88.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Fernández-Maqueda C, Gonzalo-Daganzo R, Regidor C, Martín-Donaire T, Sánchez R, Bueno JL, et al. Mesenchymal stromal cells for steroid-refractory acute GvHD. Bone Marrow Transplant. 2017;52:1577–9.

    Article 
    PubMed 

    Google Scholar
     

  • Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini FC, Krause DS, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8:315–7.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Sánchez Casado M, Quintana Díaz M, Palacios D, Hortigüela V, Marco Schulke C, García J. et al. [Relationship between the alveolar-arterial oxygen gradient and PaO2/FiO2-introducing PEEP into the model]. Med intensiva. 2012;36:329–34.

  • Gattinoni L, Vassalli F, Romitti F. Benefits and risks of the P/F approach. Intensive Care Med. 2018;44:2245–7.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Monsel A, Hauw-Berlemont C, Mebarki M, Heming N, Mayaux J, Nguekap Tchoumba O, et al. Treatment of COVID-19-associated ARDS with mesenchymal stromal cells: a multicenter randomized double-blind trial. Crit Care. 2022;26:1–14.

    Article 

    Google Scholar
     

  • Kirkham AM, Bailey AJM, Shorr R, Lalu MM, Fergusson DA, Allan DS. Systematic review and meta-analysis of randomized controlled trials of mesenchymal stromal cells to treat coronavirus disease 2019: is it too late? Cytotherapy. 2023;25:341–52.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Liu Y, Du X, Chen J, Jin Y, Peng L, Wang HHX, et al. Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. J Infect. 2020;81:e6–12.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • Liang D, Liu C, Yang M. Mesenchymal stem cells and their derived exosomes for ALI/ARDS A promising therapy. Heliyon. 2023;9:e20387.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Leng Z, Zhu R, Hou W, Feng Y, Yang Y, Han Q, et al. Transplantation of ACE2(-) mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging Dis. 2020;11:216–28.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Sánchez-Guijo F, García-Arranz M, López-Parra M, Monedero P, Mata-Martínez C, Santos A, et al. Adipose-derived mesenchymal stromal cells for the treatment of patients with severe SARS-CoV-2 pneumonia requiring mechanical ventilation. A proof of concept study. EClinicalMedicine. 2020;25:100454.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Feng Y, Huang J, Wu J, Xu Y, Chen B, Jiang L, et al. Safety and feasibility of umbilical cord mesenchymal stem cells in patients with COVID-19 pneumonia: A pilot study. Cell Prolif. 2020;53:1–8.

    Article 

    Google Scholar
     

  • Hashemian SMR, Aliannejad R, Zarrabi M, Soleimani M, Vosough M, Hosseini SE, et al. Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series. Stem Cell Res Ther. 2021;12:1–12.

    Article 

    Google Scholar
     

  • Xu X, Jiang WW, Chen LLLL, Xu Z, Zhang Q, Zhu M, et al. Evaluation of the safety and efficacy of using human menstrual blood-derived mesenchymal stromal cells in treating severe and critically ill COVID-19 patients: An exploratory clinical trial. Clin Transl Med. 2021;11:e297.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Lanzoni G, Linetsky E, Correa D, Messinger Cayetano S, Alvarez RA. et al. Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: a double-blind, phase 1/2a, randomized controlled trial. Stem Cells Transl Med. 2021;10:660–73.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Shu L, Niu C, Li R, Huang T, Wang Y, Huang M, et al. Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells. Stem Cell Res Ther. 2020;11:361.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Shi L, Huang H, Lu X, Yan X, Jiang X, Xu R, et al. Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial. Signal Transduct Target Ther. 2021;6:58.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Adas G, Cukurova Z, Yasar KK, Yilmaz R, Isiksacan N, Kasapoglu P, et al. The systematic effect of mesenchymal stem cell therapy in critical COVID-19 patients: a prospective double controlled trial. Cell Transplant. 2021;30:1–14.

    Article 

    Google Scholar
     

  • Dilogo IH, Aditianingsih D, Sugiarto A, Burhan E, Damayanti T, Sitompul PA, et al. Umbilical cord mesenchymal stromal cells as critical COVID-19 adjuvant therapy: A randomized controlled trial. Stem Cells Transl Med. 2021;10:1279–87.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Rebelatto CLK, Senegaglia AC, Franck CL, Daga DR, Shigunov P, Stimamiglio MA, et al. Safety and long-term improvement of mesenchymal stromal cell infusion in critically COVID-19 patients: a randomized clinical trial. Stem Cell Res Ther. 2022;13:1–22.

    Article 

    Google Scholar
     

  • Zhu R, Yan T, Feng Y, Liu Y, Cao H, Peng G, et al. Mesenchymal stem cell treatment improves outcome of COVID-19 patients via multiple immunomodulatory mechanisms. Cell Res. 2021;31:1244–62.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Couto PS, Al-arawe N, Filgueiras IS, Fonseca DLM, Hinterseher I, Catar RA, et al. Systematic review and meta-analysis of cell therapy for COVID-19: global clinical trial landscape, published safety/efficacy outcomes, cell product manufacturing and clinical delivery. Front Immunol. 2023;14:1200180.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Liu Q, Ma F, Zhong Y, Wang G, Hu L, Zhang Y, et al. Efficacy and safety of human umbilical cord—derived mesenchymal stem cells for COVID ‑ 19 pneumonia: a meta ‑ analysis of randomized controlled trials. Stem Cell Res Ther. 2023;14:118.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Shi L, Yuan X, Yao W, Wang S, Zhang C, Zhang B, et al. Human mesenchymal stem cells treatment for severe COVID-19: 1-year follow-up results of a randomized, double-blind, placebo-controlled trial. EBioMedicine. 2022;75:1–14.

    Article 

    Google Scholar